补充和心律失常症:一个非随机临床试验
Robert Goulden1,2, Michal Abrahamowicz1, Erin Strumpf1,3
1Department of Epidemiology, Biostatistics and Occupational Health, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
JAMA internal medicine
|December 8, 2025
概括
对于急性疾病患者,血清水平较低的患者,常规补充并不能预防心律失常,低血压或死亡. 这项研究没有发现任何证据表明在重症监护病房使用的各种治疗门中存在益处.
科学领域:
- 关键护理医学 关键护理医学
- 临床药理学 临床药理学
- 生物化学 生化学
背景情况:
- 补充剂对于患有低磁性血症的急性病患者来说是常见的,以预防心律失常症.
- 支持这种做法和特定治疗值的证据有限,观察性研究容易产生偏见.
研究的目的:
- 调查在低磁血症患者中补充是否会减少不良临床结果.
- 利用准实验设计对的影响进行因果推理.
主要方法:
- 在美国和欧洲的93个重症监护病房 (ICU) (2003-2022) 采用了模糊回归不连续性设计.
- 对比的患者刚刚超过和低于机构治疗切线 (1.6-2.0 mg/dL).
- 分析了171727例ICU住院病人的数据,重点关注动脉节律失常,低血压和测试后24小时内死亡.
主要成果:
- 没有观察到高律发生的显著差异 (风险差异:0.1%;95% CI, -4.2至6.9).
- 补充没有与降低低血压 (风险差异:1.2%,95% CI, -0.9至17.7) 或死亡 (风险差异:1.4%,95% CI, -0.6至5.3) 的相关性.
- 这些发现在所有评估的治疗切断水平中都是一致的.
结论:
- 常规补充剂在当前剂量和值为ICU患者提供没有明确的临床益处,血清水平接近治疗切断点.
- 这项研究质疑目前在这种患者群体中常规注射的做法.
- 可能需要进一步的研究来澄清在严重疾病中的作用.
相关概念视频
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.7K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.8K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.8K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.3K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
1.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.5K
Dysrhythmias VI: Management of Dysrhythmias
373
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
373
Increased pulse rate
1.0K
Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
1.0K


